12/3
06:05 pm
tngx
Tango Therapeutics (NASDAQ:TNGX) was given a new $15.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Tango Therapeutics (NASDAQ:TNGX) was given a new $15.00 price target on by analysts at Stifel Nicolaus.
11/26
07:15 am
tngx
Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/26
07:00 am
tngx
Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/21
04:24 pm
tngx
Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy [Seeking Alpha]
Medium
Report
Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy [Seeking Alpha]
11/18
12:20 pm
tngx
Tango Therapeutics (NASDAQ:TNGX) had its price target raised by analysts at B. Riley from $8.00 to $14.00. They now have a "buy" rating on the stock.
Low
Report
Tango Therapeutics (NASDAQ:TNGX) had its price target raised by analysts at B. Riley from $8.00 to $14.00. They now have a "buy" rating on the stock.
11/18
09:00 am
tngx
Tango Therapeutics (NASDAQ:TNGX) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Tango Therapeutics (NASDAQ:TNGX) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
11/14
07:08 pm
tngx
How Investors May Respond To Tango Therapeutics (TNGX) Posting First Profit on Surging Q3 Revenue [Yahoo! Finance]
Low
Report
How Investors May Respond To Tango Therapeutics (TNGX) Posting First Profit on Surging Q3 Revenue [Yahoo! Finance]
11/14
12:00 am
tngx
Tango Therapeutics (TNGX): Evaluating Valuation Following Strong Revenue Growth and Doubling Share Price [Yahoo! Finance]
Medium
Report
Tango Therapeutics (TNGX): Evaluating Valuation Following Strong Revenue Growth and Doubling Share Price [Yahoo! Finance]
11/12
07:00 am
tngx
Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference
Medium
Report
Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference
11/4
09:00 am
tngx
Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
Low
Report
Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
10/29
07:00 am
tngx
Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Low
Report
Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
10/27
10:07 am
tngx
Tango Therapeutics (NASDAQ:TNGX) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Medium
Report
Tango Therapeutics (NASDAQ:TNGX) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
10/24
08:06 am
tngx
Tango Therapeutics (NASDAQ:TNGX) had its price target raised by analysts at Guggenheim from $10.00 to $12.00. They now have a "buy" rating on the stock.
Low
Report
Tango Therapeutics (NASDAQ:TNGX) had its price target raised by analysts at Guggenheim from $10.00 to $12.00. They now have a "buy" rating on the stock.
10/23
07:20 am
tngx
Tango Therapeutics Announces $225 Million Financing
High
Report
Tango Therapeutics Announces $225 Million Financing
10/23
07:00 am
tngx
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers
High
Report
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers
10/6
07:10 am
tngx
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 [Yahoo! Finance]
Medium
Report
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 [Yahoo! Finance]
10/6
07:00 am
tngx
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025
Medium
Report
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025